Recursion Pharmaceuticals Inc【RXRX】株式ニュース

個人投資家向けのプロ仕様のツール。

プレミアム

Form 144 - Report of proposed sale of securities

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K/A - Current report: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

bwrbad 18時間前

market up big and RxRx ignored,
if quantum computing which is 7-10 years away getting attention now, then this should be in the rocket heading for stratosphere.

👍️0

TucsonPhil 20時間前

RXRX seeing some promising results in early trials. Proof of concept will solidify belief in the platform.

If cost of trials can be reduced, by less attrition of candidates, then they should see more licensing agreements, and funding, from pharma companies IMO.

👍️ 1

bwrbad 2日前

Revenue (ttm) 65.18M; Quarterly Revenue Growth (yoy) 147.60%
Total Cash (mrq) 427.65M; Total Debt (mrq) 90.62M
Shares Outstanding 6 388.94M; Float 8 252.42M
clinical trial : REC-994 in Phase 2, REC-2282 in Phase 2/3; few other in phase 1 and 2, all in less than 2 year not 15-18 years (conventional).

% Held by Institutions 1 69.40% Shares Short (Nov 15, 2024) 4 64.57M 25%

👍️0

JJ8 3日前

Rxrx share price Long Tail Up since 06 Dec 2024.

👍️0

paperman 3日前

Phase 1 news expected tonight at conference.

👍️0

paperman 3日前

Phase 1 news expected tonight at conference.

👍️0

bwrbad 4日前

this is one magnificent AI drug discovery platform - be household name like google tesla Microsoft ...

👍️0

JJ8 6日前

Bought it yesterday at $6.60

Today it's up about 22%.

Same story with 2 other stocks and they all go up today more than 20%!

Whoa! IN CREDIBLE!

👍️0

TucsonPhil 6日前

Agreed, but there will be wild swings, until they get their footing with clinical trials proving the concept works. Trade it until then, and keep one foot in the door for surprise announcements.

👍️0

bwrbad 6日前

RxRx going to be top player in future pharma drug discovery

👍️0

TucsonPhil 6日前

Good company, but MMs playing games this morning. Insider buying? News? Who knows? Missed this runup, but will wait for the dip again.

👍️0

bwrbad 7日前

GOOG -- RxRx -- NVDA -- RxRx -- MSFT

👍️0

bwrbad 1週前

agree but better, much bigger scope, on way to become a high flying company of the future
price target 150 in two year

👍️0

uksausage 1週前

no it is the PLTR of Drug discovery
both rely on NVDA to run fast

👍️0

bwrbad 1週前

started buying little little- this is NVDA of DRUG DISCOVERY

👍️0

ToucanYoucan 1週前

$RXRX - That's why I'm planning to steadily accumulate shares - with the hope that one or more of these new treatments materializes.

👍️0

bwrbad 1週前

high potential if delivers,

👍️0

TucsonPhil 1週前

Good gains in past week, but looks like it is getting ready to drift lower again.

👍️0

TucsonPhil 1週前

First patient dosed.

https://ir.recursion.com/news-releases/news-release-details/recursion-announces-first-patient-dosed-phase-12-clinical-study

👍️0

lambchops 2週前

Glad to see the uptick! Was beaten down for a while. Too good of stock to be down for long.

LC

RXRX

👍️ 1

ToucanYoucan 2週前

$RXRX - Having a huge day here!!

👍️0

ToucanYoucan 2週前

$RXRX - Nice move up today! This will take a little time to find its footing pps-wise after the merger...imo

👍️0

TucsonPhil 4週前

Many foreign countries supplying pharmaceuticals to U.S. at exorbitant markups.

Will anything be done about that? I do not believe tariffs will help with that problem, since people either pay, whatever the cost, or suffer and die.

https://x.com/RecursionPharma/status/1841453309342740925

👍️0

TucsonPhil 2月前

So many clinical trials in work, but for this to translate to value, they will need to show high efficacy and a much shorter time-to-market, using Recursion platform. The problem may be that Recursion can identify promising candidates quickly, but the slow-moving follow-on processes will still eat up valuable time. The value proposition here is the decrease in attrition, for candidates that fail in early stage trials.

https://ir.recursion.com/news-releases/news-release-details/recursion-gives-guidance-seven-clinical-readouts-within-18

https://www.recursion.com/pipeline

https://www.stockscores.com/charts/charts/?ticker=RXRX

👍️0

lambchops 3月前

Yes. Good stock to put on watchlist IMO.
Still reasonably cheap. Check MACD.

LC

RXRX

👍️0

mick 3月前

diamond in the ruff

RXRX
Recursion Pharmaceuticals Inc
6.32
0.20 (3.27%)
Volume: 3,082,418
Day Range: 6.055 - 6.32
Last Trade Time: 4:28:47 PM EDT

👍️0

mick 3月前

RXRX
Recursion Pharmaceuticals Inc
5.95
-0.22 (-3.57%)
Volume: 4,577,882
Day Range: 5.895 - 6.30
Last Trade Time: 7:58:59 PM EDT

👍️0

lambchops 3月前

Yes, I've been adding shares of RXRX this week.

LC

RXRX

👍️0

TucsonPhil 3月前

Looks.like a little dilution, but a good buying opportunity, to add some more.

👍️0

lambchops 3月前

Judging on the reaction some investors must not have liked it either.Will be a strong company into RXRX.I like buying good companies that have a downdraft. They usually come back strong.
Please note I own shares in this company.

LC

RXRX

👍️0

TucsonPhil 3月前

I had not seen that merger announcement. Never came across in my broker news feed.

👍️0

lambchops 3月前

Did you see the possible merger news?

LC

RXRX

👍️0

TucsonPhil 3月前

Running millions of tests per week, to find promising drug candidates.

What we do not know, is how many candidates have entered clinical trials.

When news pops about RXRX origination of promising cures, this will skyrocket.

Oops, missed this one:

https://ir.recursion.com/news-releases/news-release-details/recursion-announces-phase-2-data-rec-994-first-disease

👍️0

lambchops 3月前

Looks ready to move IMO.

LC

RXRX

👍️0

TucsonPhil 4月前

Looking for a move into the 9.25-9.50 range within the next few weeks.

👍️0

lambchops 4月前

RXRX looks ready for another move upward.

Looks like RXRX is making an upward move.

👍️0

lambchops 4月前

I like RXRX even better!

LC

GOOD to own, Rxrx

👍️0

lambchops 4月前

How do you like RXRX at $6.65?

Hold this one until they discover a promising drug candidate, then play the spike and repurchase on the subsequent slump. Ofc, if they do start identifying promising drug candidates, then it could just keep going up, after proof of concept is shown.

👍️0

mick 5月前

RXRX
Recursion Pharmaceuticals Inc
7.9485
-0.4015 (-4.81%)
Volume: 2,346,108
Day Range: 7.94 - 8.48
Last Trade Time: 2:15:15 PM EDT

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Recursion Pharmaceuticals Inc (RXRX)

個人投資家向けのプロ仕様のツール。

RXRX ニュース

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K/A - Current report: [Amend]

Form 8-K/A - Current report: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

RXRX Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Recursion Pharmaceuticals Inc (RXRX) ニュース

Recursion Pharmaceuticals Inc (RXRX)

個人投資家向けのプロ仕様のツール。

RXRX ニュース

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K/A - Current report: [Amend]

Form 8-K/A - Current report: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

RXRX Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手